戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 od parameters, leukocyte depletion, and bone marrow hypoplasia.
2 characterized by peripheral pancytopenia and marrow hypoplasia.
3 asia, extramedullary hematopoiesis, and bone marrow hypoplasia.
4 y reduced BCNU-induced mortality due to bone marrow hypoplasia.
5 eded the development of neutropenia and bone-marrow hypoplasia.
6  (F1) recipients failed to induce the severe marrow hypoplasia and fatal pancytopenia that is produce
7    Here, histology and flow cytometry reveal marrow hypoplasia and impaired hematopoiesis in all coll
8 gnificant thrombocytopenia secondary to both marrow hypoplasia and increased PLT destruction.
9 ich is characterized by immune-mediated bone marrow hypoplasia and pancytopenia, can be treated effec
10 o, including red blood cell deficiency, bone marrow hypoplasia, and defective thymopoiesis.
11 t in the production of red blood cells, bone marrow hypoplasia, and runting.
12  one of six trials required documentation of marrow hypoplasia before CSF use.
13 M oligoclonal T-cell infiltration and severe marrow hypoplasia indicated by approximately 10-fold dec
14                                              Marrow hypoplasia occurred between days 14 and 28 in 12
15                                              Marrow hypoplasia occurred between days 14 and 28 in 73%
16 res with the development of pancytopenia and marrow hypoplasia, validating a major role for the Fas/F
17                    Overall, postchemotherapy marrow hypoplasia was achieved in 33 patients.
18 hether leukemia response or documentation of marrow hypoplasia was required before cytokine use, and

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。